Teva Pharmaceutical Industries Ltd (TEVA)
17.08
+0.06
(+0.32%)
USD |
NYSE |
Nov 21, 16:00
17.08
0.00 (0.00%)
After-Hours: 19:56
Teva Pharmaceutical Industries Revenue (Quarterly): 4.331B for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 4.331B |
| June 30, 2024 | 4.164B |
| March 31, 2024 | 3.819B |
| December 31, 2023 | 4.457B |
| September 30, 2023 | 3.85B |
| June 30, 2023 | 3.877B |
| March 31, 2023 | 3.662B |
| December 31, 2022 | 3.883B |
| September 30, 2022 | 3.595B |
| June 30, 2022 | 3.785B |
| March 31, 2022 | 3.661B |
| December 31, 2021 | 4.10B |
| September 30, 2021 | 3.886B |
| June 30, 2021 | 3.91B |
| March 31, 2021 | 3.982B |
| December 31, 2020 | 4.452B |
| September 30, 2020 | 3.978B |
| June 30, 2020 | 3.87B |
| March 31, 2020 | 4.357B |
| December 31, 2019 | 4.467B |
| September 30, 2019 | 4.093B |
| June 30, 2019 | 4.176B |
| March 31, 2019 | 4.147B |
| December 31, 2018 | 3.976B |
| September 30, 2018 | 4.529B |
| Date | Value |
|---|---|
| June 30, 2018 | 4.701B |
| March 31, 2018 | 5.065B |
| December 31, 2017 | 4.866B |
| September 30, 2017 | 5.617B |
| June 30, 2017 | 5.72B |
| March 31, 2017 | 5.65B |
| December 31, 2016 | 6.492B |
| September 30, 2016 | 5.563B |
| June 30, 2016 | 5.038B |
| March 31, 2016 | 4.81B |
| December 31, 2015 | 4.881B |
| September 30, 2015 | 4.823B |
| June 30, 2015 | 4.966B |
| March 31, 2015 | 4.982B |
| December 31, 2014 | 5.168B |
| September 30, 2014 | 5.058B |
| June 30, 2014 | 5.045B |
| March 31, 2014 | 5.001B |
| December 31, 2013 | 5.43B |
| September 30, 2013 | 5.059B |
| June 30, 2013 | 4.924B |
| March 31, 2013 | 4.901B |
| December 31, 2012 | 5.249B |
| September 30, 2012 | 4.972B |
| June 30, 2012 | 4.994B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
3.595B
Minimum
Sep 2022
4.467B
Maximum
Dec 2019
4.004B
Average
3.898B
Median
Revenue (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 141.52M |
| Compugen Ltd | 17.13M |
| Pluri Inc | 0.326M |
| Can Fite Biofarma Ltd | 0.155M |
| BiomX Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -437.00M |
| Total Expenses (Quarterly) | 3.347B |
| EPS Diluted (Quarterly) | -0.39 |
| Enterprise Value | 35.28B |
| Gross Profit Margin (Quarterly) | 49.60% |
| Profit Margin (Quarterly) | -10.09% |
| Earnings Yield | -4.98% |
| Operating Earnings Yield | 19.36% |
| Normalized Earnings Yield | 9.002 |